T cells respond to peptide antigen in association with MHC products on antigen-presenting cells (APCs). A number of accessory or costimulatory molecules have been identified that also contribute to T cell activation. Several of the known accessory molecules are expressed by freshly isolated dendritic cells, a distinctive leukocyte that is the most potent APC for the initiation of primary T cell responses. These include ICAM-1 (CD54), LFA-3 (CD58), and class I and II MHC products. Dendritic cells also constitutively express the accessory ligand for CD28, B7/BB1, which has not been previously identified on circulating leukocytes freshly isolated from peripheral blood. Dendritic cell expression of both B7/BB1 and ICAM-1 (CD54) increases after binding to allogeneic T cells. Individual mAbs against several of the respective accessory T cell receptors, e.g., anti-CD2, anti-CD4, anti-CD1 la, and anti-CD28, inhibit T cell proliferation in the dendritic cell-stimulated allogeneic mixed leukocyte reaction (MLR) by 40-70%. Combinations of these mAbs are synergistic in achieving near total inhibition. Other T cell-reactive mAbs, e.g., anti-CD5 and anti-CD45, are not inhibitory. Lymphokine secretion and blast transformation are similarly reduced when active accessory ligand-receptor interactions are blocked in the dendritic cell-stimulated allogeneic MLR. Dendritic cells are unusual in their comparably higher expression of accessory ligands, among which B7/BB1 can now be included. These are pertinent to the efficiency with which dendritic cells in small numbers elicit strong primary T cell proliferative and effector responses. (J. Clin. Invest. 1992.
Antigen-presenting cells (APCs)' express cell surface molecules that are known to enhance T cell responses to peptide-MHC complexes (1) (2) (3) . These costimulatory or accessory molecules pair with specific receptors on the T cell. Several ofthese molecular couples have been characterized: LFA-3 (CD58) with CD2 (4, 5), ICAM-1 (CD54) with LFA-1 (CD I I a) (6) , B7/BB 1 with CD28 (7) (8) (9) (10) and/or CTLA-4 (11), CD72 with CD5 (12) , and class I or II MHC with CD8 (13) or CD4 (14) , respectively. However, these accessory ligands have not always been identified on circulating leukocytes, and their roles have usually been evaluated using expanded T cell clones already activated by antigen and heterogeneous feeder cells.
Prior work has established that dendritic cells, which represent a trace but distinctive leukocyte subset, are the most potent APC for the induction of primary, antigen-specific T cell responses in vitro and in situ (15) . Among the known accessory couples, the interaction between B7/BB 1 and CD28 is the only one that appears to stimulate T cell proliferation by a direct effect on IL-2 production (16) (17) (18) (19) . We therefore investigated whether dendritic cells expressed the accessory molecule B7/ BB1, in addition to their known high expression of ICAM-1 (CD54), LFA-3 (CD58), and MHC class I and II products (20) (21) (22) . We report that all are expressed by dendritic cells and that B7/BB1 and ICAM-1 (CD54) specifically increase after dendritic cell binding to primary CD4+ lymphocytes. Using mAbs directed against the T cell receptors for these costimulatory molecules, we also demonstrate the functional roles of these accessory couples in the complete activation of primary T cells in the allogeneic mixed leukocyte reaction (MLR).
Mg2e-free saline buffers ([PBS or HBSS] or bovine calf serum [BCS];
JRH Biosciences) 5% vol/vol in RPMI were used for cell washes. All sera were heat-inactivated at 560C for 30 min to deplete complement. All cell cultures were maintained at 370C in humidified 7% Co2.
Monoclonal antibodies mAbs used in the functional in vitro assays and for the isolation of T lymphocyte subsets were: anti-HLA class II, DR-specific (L243, IgG2a; Xth International Histocompatibility Workshop), and monomorphic DR/DQ-specific (9. [24, 25] ); anti-CD54 (LB2, IgG2a, FITC-conjugated; E. A. Clark); anti-CD56 (Leu19, IgGl; Becton-Dickinson Microbiology Sys.); anti-CD57 (Leu7, IgM; Becton Dickinson Microbiology Sys.); anti-CD58 (LFA-3, IgGl, HB 205; ATCC); anti-BBl (anti-B cell activation antigen B7/ BB 1, IgM, both unconjugated and FITC-conjugated; E. A. Clark [26] ). All murine anti-human mAbs used in the functional in vitro assays were purified as whole immunoglobulin from murine ascites or serumfree hybridoma supernatants and quantified at OD280. F(ab')2 fragments were not used in the functional assays, as blood dendritic cells do not have detectable FcR (27) . For isolation of lymphocyte subsets, either murine ascites or hybridoma supernatants were applied at previously determined effective concentrations. Cytofluorographic analyses of T lymphocyte subset purity and accessory ligand expression were performed on a FACScan" instrument (Becton-Dickinson Immunocytometry Systems, Mountain View, CA). Commercial mAbs for staining were purchased already conjugated to either FITC or PE; otherwise, FITC-conjugated F(ab')2 goat anti-mouse IgG + IgM (4353; TAGO, Inc., Burlingame, CA) was used as a second-step reagent for indirect staining. We FITC-conjugated anti-BB I and LB2 (CD54) according to standard methods (28) . Stained PBMC and preparation ofleukocyte subpopulations PBMC and the mononuclear subpopulations of interest were prepared according to previously published procedures (20, 27, 29 (30) .
Enrichment ofdendritic cells (20, 27, 29) . After the Er-fraction had been cultured -36 h in RPMI 10% NHS, the nonadherent cells were collected and panned twice over human Ig-coated (10 mg/ml; Cappel, Organon Teknika) petri dishes to deplete contaminant monocytes, which adhered via their Fc receptors (27) . A final adherence step to tissue culture plastic was performed at 37°C for [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] min. This Er-FcR-plastic nonadherent population was resuspended, overlaid on 3 ml of 14.5 g% metrizamide [20, 29] whether T lymphoblasts themselves could express B7/BB 1. We compared APC-free, Con A/phorbol myristate acetate (PMA)-stimulated T cells with unstimulated T cell controls for ICAM-1 (CD54) and B7/BB1 expression. We confirmed activation by the expression of p55IL-2R (CD25; Fig. 1 g) . These CD25+ T lymphoblasts increased their expression ofthe widely distributed ICAM-1 (CD54) marker as expected (Fig. 1 h) . However, B7/BB1 was not expressed significantly above background by either the unstimulated controls or the Con A/ PMA-elicited T lymphoblasts (Fig. 1 i) . We therefore infer that T lymphocytes do not contribute to the increased B7/BB1 found on clustered dendritic cells in the allogeneic MLR. The accessory ligands expressed by blood dendritic cells are involved in stimulating primary T cellproliferative responses to alloantigen. We first studied the function ofthe CD28:B7/BB I couple, as blood dendritic cells constitute a primary leukocyte subpopulation expressing B7/BB 1. The function of CD28 and B7/BB1 in allogeneic MLRs had previously only been assessed using B lymphoblastoid cell line stimulators (36) . We therefore stimulated CD4+ responder T cells with allogeneic dendritic cells in the presence of mAbs against B7/BB 1 and its receptor CD28, singly and in combination. A representative experiment is shown in Fig. 2 . Compared with isotype-matched controls, anti-CD28 consistently inhibited the primary allogeneic MLR by 40-70% (representative of 10 experiments). Anti-BBl was typically less inhibitory than anti-CD28 (26-37% inhibition, cf. IgM control in this experiment). The combination of mAbs against BB1 and CD28, however, did not significantly increase the inhibition effected by either mAb alone, consistent with involvement of the same ligand:receptor couple in the dendritic cell T cell system. In contrast, the combination of anti-CD28 and anti-CD2 (TS2/18) was additive in its inhibitory effects, confirming interactions between more than one accessory ligand/receptor pair.
We then studied the function of other accessory ligands expressed by circulating blood dendritic cells (Table I) . Intact mAbs against the T cell accessory molecules, CD2, CD4, CDl la, and CD28, were used to monitor inhibition of dendritic cell ligand binding and resultant T cell proliferation. The dose of mAb(s) was varied while the responder:stimulator ratio was held constant ( anti-B7/BBl; . isotype-matched control. T lymphoblast expression of these ligands was also analyzed using highly purified, APC-free CD34/CD4' T cells stimulated by Con A/PMA: (g, h, i) . unstimulated T cells;
Con A/PMA-stimulated blasts; . isotype-matched controls. T cell activation was confirmed by the expression of p55IL-2R/CD25: (g) unstimulated CD3+/CD4+ = 2% CD25+, 96% CD25-; Con A/PMA-stimulated CD3+/CD4+ blasts = 82% CD25+, 16% CD25-. Cytofluorographs are representative of six experiments. Dendritic cells used here were obtained from the Er-FcR-, plastic nonadherent, metrizamide interface fraction. Increased purity of the DC population to 80-90%, achieved by panning depletion of residual CD45RA+ (4G10) and CD14+ (3C10) cells in the metrizamide interface, did not alter the results shown.
nary experiments showed CD4+/CD45RA-and CD4+/ CD45RO-subsets were indistinguishable in their inhibition by the various mAbs tested. We also compared T cells obtained by E-rosetting with those obtained by nonadherence to tissue culture plastic after 1 h incubation of PBMC, eluted from nylon wool columns in either case. There were no differences be- MAbs that inhibit proliferation similarly affect IL-2 release and blast transformation in the allogeneic MLR. The amount of 3HTdR incorporation on d4-5 is a distal measurement of accessory cell-T cell interactions that have occurred much earlier in the dendritic cell-stimulated MLR. We therefore evaluated whether two other parameters of T cell activation, IL-2 secretion and blast transformation, were concordant with the results obtained from 3HTdR incorporation in parallel MLRs cultured under identical conditions. As shown in Fig. 3 , these two independently measured parameters, IL-2 release by 48 h of culture and percent blast transformation on d4-5, were both highly correlated with actual T cell proliferation. We conclude that anti-T cell mAbs with specificity for accessory molecule receptors not only inhibit proliferation in the dendritic cellstimulated allogeneic MLRs, but similarly decrease IL-2 release and actual blast transformation.
Dendritic cells deliver important costimulatory signals early in the primary allogeneic MLR. As dendritic cells are the most potent leukocyte for the initiation ofT cell responses to alloantigen and mitogen (27) , we hypothesized that their costimulatory signals were important for their accessory cell function early in the MLR. As illustrated in Fig. 4 , addition of mAbs against T cell accessory receptor molecules from the outset of the MLR culture was needed to achieve significant inhibition. Equivalent inhibition was achieved at any dose ofdendritic cell stimulators used (T:DC 30:1 illustrated; 10:1 and 100:1, not shown). Addition of mAbs at 24 or 48 h was less effective.
Discussion
Primary antigen-specific T cell responses require peptide antigen presented in association with surface MHC products on APCs (1). Antigen-presentation alone is insufficient, however, to initiate effective T cell immunity (1, 32) . The complete activation of T lymphocytes in a primary response therefore depends on the concerted delivery by APCs of several accessory or costimulatory signals in addition to Ag/MHC (1-3) .
We present evidence here that human dendritic cells freshly isolated from peripheral blood express B7/BB 1, the physiologic ligand for the CD28 T cell accessory molecule. Dendritic cells in blood (20) and skin (21, 22) Fig. 2 ). $ Addition of ctCD4 to this combination did not increase the already maximal inhibition (see also Fig. 2 (6) , and the third ligand has not been characterized (42). Antigen-presentation is significantly more efficient by virtue of a functional ICAM-1 :LFA-1 (CD54:CD 11 a) interaction (43, 44) , and stimulation via either CD2 or CD3 increases LFA-1 (CD I I a) binding avidity for ICAM-1 (CD54) (45, 46) . ICAM-1 (CD54) and the f2 leukocyte integrins are widely distributed and are present on dendritic cells (CD54, CDl la/18, CDl lc/18 [20] ), T lymphocytes (CDl la/18 [6] ), and T lymphoblasts (CD54 [6] ; see also Results). CD4 is a co-recognition element for class II MHC ( 14, 47) , engaging a specific MHC-peptide component together with the CD3/TCR complex. CD4 is coupled to a lymphocytespecific tyrosine kinase (p56lck) that phosphorylates CD3 (48, 49) and may signal T lymphocytes in this manner. Lastly, CD2 is a pan-T cell surface antigen that binds the broadly distributed LFA-3 (CD58) ligand and is involved in both T cell adhe-sion and activation (4, 5) . CD2 signals T cell activation in conjunction with the CD3/TCR complex (50), via its cytoplasmic domain (5 were cultured in triplicate flat-bottomed microwells in the presence of mAbs to accessory ligands or receptors, singly and in combination, versus isotype-matched controls or no mAb. Supernatants were collected from one MLR set at 48 h and assayed for IL-2, based on their ability to support growth of a CTLL2 line (33) . Results are expressed in terms of IU rhIL-2/ml (1 Cetus Unit = 6 IU rhIL-2). The remaining two sets of MLRs were left in culture. One set was pulsed with I uCi3HTdR/microwell for 8 h on d4 --5 to assess proliferation. The other set was simultaneously stained with 0.5% vol/vol propidium iodide and monitored cytofluorographically for viable blast transformation, based on increased forward scatter (compared with unstimulated CD4' T cell controls) and negative FL2 fluorescence (nonviable cells are propidium iodide positive in the FL2 channel). The amount of 3HTdR incorporation was compared with the amount of IL-2 secretion (r = 0.925) or percent blast transformation (r = 0.975) for each MLR condition tested (e.g., presence or absence of mAbs at variable doses, as used in Fig. 2 and Table I ). (27) . Blocking single accessory ligand:receptor couples only partially inhibited T cell responses in a primary allogeneic MLR. Complete inhibition required interference with at least three accessory ligand:receptor interactions. Alternatively, we observed a trend toward more complete inhibition by pairwise combinations of mAbs when the amount of antigen was reduced (i.e., fewer stimulatory allogeneic dendritic cells in the MLR). T cell proliferation, as well as IL-2 secretion and blast transformation, were all affected. Accessory signals seemed to be required in the first 24 h of a primary T cell response to alloantigen, since mAbs were substantially less inhibitory once proliferation had commenced. This was true whether we added anti-accessory receptor mAbs to MLR cultures at 24 or 48 h, compared with time 0, or whether these mAbs were added to antigen-specific T cell/dendritic cell clusters that had been separated from nonclustered T cells after 40 h initial culture (latter not shown). Anti-accessory molecule mAbs were less effective when added after the initiation of the MLR, either because costimulatory signals had already been delivered to the T cells, increased accessory ligand expression escaped inhibition, steric accessibility into the dendritic cell T lymphocyte clusters was limited, or the number of stimulatory dendritic cells was so high in the clusters as to restrict the inhibition that could be achieved. T cell-reactive, isotype-matched control mAbs against two other molecules involved in T cell signaling and activation, CD5 and CD45 (37), were never inhibitory under any condition. A similar analysis has been conducted of human tonsillar dendritic cells in T cell oxidative mitogenesis (51) , and most of these same accessory couples contributed to function (except B7/BB1:CD28 which was unknown at that time). Those involved in cell-cell adhesion also blocked clustering, which we did not observe in the human dendritic cellstimulated allogeneic MLR and which has also not been documented in the murine MLR (52) . CD3/TCR occupancy by antigen/MHC is insufficient to initiate primary T cell responses, as several additional costimulatory signals must be delivered by active APCs (1) (2) (3) . This is underscored by our finding that complete inhibition of IL-2 secretion, blast transformation, and proliferation by primary T cells responding to alloantigen requires mAb block at several key points. These molecular couples are probably most integral to APC:T cell interactions when T cells are in a quiescent or unprimed state or when the amount of presented antigen is low, resulting in more stringent APC requirements (27, 32, 35, 53, 54) . The use of mitogens or chronically stimulated T cell lines as responder populations may obscure relevant physiologic signals. B7/BB1, ICAM-1 (CD54), and LFA-3 (CD58) probably work in conjunction with antigen/MHC on dendritic cells, each delivering a distinct costimulatory signal to the T lymphocyte (3). B7/BB1 and ICAM-1 (CD54), although present on circulating dendritic cells, are upregulated after binding to T cells, presumably increasing T cell transcription and release of IL-2 via CD28 (8, 9, (16) (17) (18) (19) , as well as binding avidity via CDl la (45, 46) . Adhesion should be bidirectional, as ICAM-1 (CD54) also appears on T lymphoblasts and can interact with LFA-1 (CDl la:CD1 8) on dendritic cells. B lymphoblastoid transformation (7, 26, 36, 38, 39) or monocyte exposure to y-IFN (40) upregulates each cell's expression ofmany of these same accessory ligands. This should foster productive interaction with T cells already sensitized by dendritic cells, maintaining and amplifying an effective immune response. Different APCs therefore do not differ qualitatively in their capacity to express these accessory ligands, but in their quantitative expression and the factors regulating same. We conclude that dendritic cells are unusual among circulating leukocytes in their comparably higher expression of accessory ligands, and that these are pertinent to the efficiency with which dendritic cells in small numbers elicit strong primary T cell proliferative and effector responses.
